Thomas Jefferson University School of Medicine, Philadelphia, Pennsylvania 19107, USA.
J Clin Invest. 2010 Sep;120(9):3102-5. doi: 10.1172/JCI44422. Epub 2010 Aug 25.
The discovery several years ago that fibroblasts and other somatic cells from mice and humans can be reprogrammed to become inducible pluripotent stem (iPS) cells has created enthusiasm for their potential applications in regenerative medicine and for modeling human diseases. Two independent studies in this issue of the JCI provide evidence that iPS cells represent a promising source of hepatocytes for a wide range of applications, including cell transplantation, drug toxicity testing, patient-specific disease modeling, and even ex vivo gene therapy. But how far have we come?
几年前，人们发现从小鼠和人身上分离的成纤维细胞和其他体细胞可以被重编程为诱导多能干细胞（iPS 细胞），这一发现激发了人们对 iPS 细胞在再生医学和人类疾病模型方面的潜在应用的热情。本期《临床检查杂志》（JCI）上的两项独立研究提供了证据，表明 iPS 细胞是一种有前途的肝细胞来源，可广泛应用于细胞移植、药物毒性测试、患者特异性疾病建模，甚至体外基因治疗等领域。但是，我们已经走了多远？
